Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study

Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study

Bibliographic Details
Main Authors:	Rosalba D’Alessandro, Maria Grazia Refolo, Annalisa Schirizzi, Giampiero De Leonardis, Rossella Donghia, Vito Guerra, Gianluigi Giannelli, Ivan Roberto Lolli, Maria Maddalena Laterza, Ferdinando De Vita, Caterina Messa, Claudio Lotesoriere
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Oncology
Subjects:	angiogenesis gastric cancer target therapy biomarkers cancer progression
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1187014/full

Similar Items

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study
by: Rosalba D’Alessandro, et al.
Published: (2022-04-01)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
by: Annalisa Schirizzi, et al.
Published: (2023-02-01)

VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment
by: Annalisa Schirizzi, et al.
Published: (2023-10-01)

Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
by: Annalisa Schirizzi, et al.
Published: (2023-04-01)

Ramucirumab combined with paclitaxel as the second-line chemotherapy for elderly patients with disseminated gastric cancer
by: T. A. Titova, et al.
Published: (2018-07-01)

Ramucirumab: Boon or bane
by: Priya Tiwari
Published: (2016-09-01)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
by: Rosalba D’Alessandro, et al.
Published: (2019-06-01)

Inflammatory Mechanisms of HCC Development
by: Maria Grazia Refolo, et al.
Published: (2020-03-01)

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites
by: Hiroshi Matsumoto, et al.
Published: (2018-01-01)

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
by: Seung Tae Kim, et al.
Published: (2021-01-01)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
by: Mashiro Okunaka, et al.
Published: (2020-11-01)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
by: Maria Angeles Gil-Delgado, et al.
Published: (2018-08-01)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
by: Kosuke Fukuda, et al.
Published: (2022-04-01)

Ramucirumab with paclitaxel or FOLFIRI as second-line treatment in docetaxel-pre-treated patients with metastatic gastric cancer in real-world setting
by: N. S. Besova, et al.
Published: (2021-06-01)

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia
by: N. S. Besova, et al.
Published: (2018-07-01)

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer
by: Mehta R, et al.
Published: (2020-01-01)

<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
by: Francesco Graziano, et al.
Published: (2020-07-01)

Case report of the rapid achievement of sustained and long-term remission resulting from the use of ramucirumab plus paclitaxel in the second-line treatment of a patient with disseminated gastric adenocarcinoma
by: T. A. Titova, et al.
Published: (2018-07-01)

Therapeutic response to ramucirumab + folfiri in patients with metastatic gastric cancer
by: Hamid Rezvani, et al.
Published: (2022-01-01)

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?
by: Ming-Huang Chen, et al.
Published: (2021-07-01)

Fulminant Fournier’s gangrene in a patient with gastric cancer treated with ramucirumab and paclitaxel
by: Zoran Rakusic, et al.
Published: (2020-08-01)

Endoscopic Ultrasound-Guided Drainage of Intra-Abdominal Abscess after Gastric Perforation in a Patient Receiving Ramucirumab and Paclitaxel for Advanced Gastric Cancer
by: Koichiro Mandai, et al.
Published: (2017-01-01)

Contribution of macro- and micronutrients intake to gastrointestinal cancer mortality in the ONCONUT cohort: Classical vs. modern approaches
by: Rossella Donghia, et al.
Published: (2023-01-01)

Optimizing treatment duration with ramucirumab and paclitaxel by managing chemotherapy-associated toxicity: Review of four cases
by: Man Yee Merl, et al.
Published: (2020-10-01)

Update Overview of the Role of Angiopoietins in Lung Cancer
by: Dimitris Tsakogiannis, et al.
Published: (2021-11-01)

Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer
by: Yi-Hsin Liang, et al.
Published: (2022-10-01)

A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
by: Shinya Urakawa, et al.
Published: (2017-12-01)

Distinct Clinical Impact and Biological Function of Angiopoietin and Angiopoietin-like Proteins in Human Breast Cancer
by: Hui Yang, et al.
Published: (2021-09-01)

Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids
by: Adriana Romanzi, et al.
Published: (2023-12-01)

The ratio of serum Angiopoietin-1 to Angiopoietin-2 in patients with cervical cancer is a valuable diagnostic and prognostic biomarker
by: Ping Yang, et al.
Published: (2017-05-01)

Ramucirumab therapy in patients with advanced gastric cancer: discussion of a case series
by: R V Orlova, et al.
Published: (2018-03-01)

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells
by: Marta Celegato, et al.
Published: (2021-12-01)

Angiopoietin-like proteins: a comprehensive look
by: Gaetano eSantulli
Published: (2014-01-01)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
by: Tadashi Nishimura, et al.
Published: (2022-06-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Real-World Data on Second-Line Therapy with Ramucirumab for Metastatic Gastric Cancer: A Two-Center Study on Romanian Population
by: Diana Galos, et al.
Published: (2023-12-01)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.
by: Sini Li, et al.
Published: (2020-01-01)

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia
by: N. S. Besova, et al.
Published: (2019-12-01)

Choice of anti-angiogenic agents in second-line treatment in patients with metastatic colon cancer: bevacizumab, aflibercept, ramucirumab (a literature review)
by: M Iu Fedyanin
Published: (2015-09-01)

Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study
by: Katsuhiko Nara, et al.
Published: (2023-10-01)